Clinical trial · no report yet · Phase 3
NCT06337318
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- NCT06337318 ↗
- Recruiting
- National Cancer Institute (NCI)
- 11 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 7 | |
| Podcasts | 3 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Classic Follicular Lymphoma; Follicular Lymphoma With Unusual Cytological Features
- Interventions
- Biospecimen Collection; Computed Tomography; Mosunetuzumab; Positron Emission Tomography; Rituximab; Rituximab and Hyaluronidase Human
- Arms
- Arm I (Rituximab, rituximab and hyaluronidase) · Experimental
- Arm II (Mosunetuzumab) · Experimental
- Enrollment
- 600 (estimated)
- Primary outcomes
- 3-year milestone progression free survival (PFS)
- PFS
- Sponsor
- National Cancer Institute (NCI)
- Start
- Oct 23, 2024
- Primary completion
- Mar 31, 2032 (estimated)
- Results posted
- No
- Registry record
- NCT06337318 · updated Oct 9, 2026